Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 262-269

  Bouhali, Tarek ^a   Brisson, Diane ^a   St Pierre, Julie ^a,c   Tremblay, Gerald ^a   Perron, Patrice ^a   Laprise, Catherine ^a,b   Vohl, Marie Claude ^d   Vissers, Maud N ^e   Hutten, Barbara A ^e   Després, Jean Pierre ^c   Kastelein, John J P ^e   Gaudet, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DU QUÉBEC À CHICOUTIMI   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Adipocytokines; Adiponectin; Coronary artery disease; Hypercholesterolemia; Risk factors

Indexed keywords

ADIPONECTIN;

ABDOMINAL FAT; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK FACTOR;

ADIPONECTIN; ADULT; AGE OF ONSET; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 38049007023     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.10.035     Document Type: Article

References (43)

1. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34 2 (2003) 154-156
2. Garcia C.K., Wilund K., Arca M., et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292 5520 (2001) 1394-1398
3. Goldstein J. Familial hypercholesterolemia. In: Scriver C.B., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic basis of inherited disease. 8th ed. (2000), McGraw-Hill Book Co., New York 2863-2913
4. Moorjani S., Roy M., Torres A., et al. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet 341 8856 (1993) 1303-1306
5. Lansberg P.J., Tuzgol S., van de Ree M.A., Defesche J.C., and Kastelein J.J. Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands. Ned Tijdschr Geneeskd 144 30 (2000) 1437-1440
6. Moorjani S., Roy M., Gagne C., et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 9 2 (1989) 211-216
7. Vohl M.C., Moorjani S., Roy M., et al. Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec. Clin Genet 52 1 (1997) 1-6
8. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106 3 (2002) 286-288
9. Gaudet D., Vohl M.C., Perron P., et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 97 9 (1998) 871-877
10. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 256 6 (2004) 482-490
11. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257 2 (2005) 167-175
12. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 1 (1999) 79-83
13. Nakano Y., Tobe T., Choi-Miura N.H., Mazda T., and Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120 4 (1996) 803-812
14. Cnop M., Havel P.J., Utzschneider K.M., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46 4 (2003) 459-469
15. Kondo H., Shimomura I., Matsukawa Y., et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51 7 (2002) 2325-2328
16. Cote M., Mauriege P., Bergeron J., et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 90 3 (2005) 1434-1439
17. Scriver C.R. Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet 2 (2001) 69-101
18. Gaudet D., Tremblay G., Perron P., et al. Familial hypercholesterolemia in eastern Quebec: a public health problem? The experience of the hyperlipidemia clinic of Chicoutimi. Union Med Can 124 2 (1995) 54-60
19. Gaudet D., Gagne C., Perron P., Couture P., and Tonstad S. Ethical issues in molecular screening for heterozygous familial hypercholesterolemia: the complexity of dealing with genetic susceptibility to coronary artery disease. Community Genet 2 1 (1999) 2-8
20. Ma Y.H., Betard C., Roy M., Davignon J., and Kessling A.M. Identification of a second "French Canadian" LDL receptor gene deletion and development of a rapid method to detect both deletions. Clin Genet 36 4 (1989) 219-228
21. Couture P., Vohl M.C., Gagne C., et al. Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. Hum Mutat Suppl 1 (1998) S226-S231
22. Leitersdorf E., Tobin E.J., Davignon J., and Hobbs H.H. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 85 4 (1990) 1014-1023
23. Vohl M.C., Couture P., Moorjani S., et al. Rapid restriction fragment analysis for screening four point mutations of the low-density lipoprotein receptor gene in French Canadians. Hum Mutat 6 3 (1995) 243-246
24. W.H.O. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of Diabetes mellitus (1999), World Health Organization, Geneva
25. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 3 (2000) 959-969
26. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 9 (1955) 1345-1353
27. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997;20(7):1183-97.
28. Laurell C.B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 15 1 (1966) 45-52
29. Standardization of anthropometric measurements. In: Lohman T.R.A., and Martorel R. (Eds). The Airlie (VA) consensus conference. Human Kinetics, Champaign, IL (1988) 39-80
30. Gaudet D., Arsenault S., Belanger C., et al. Procedure to protect confidentiality of familial data in community genetics and genomic research. Clin Genet 55 4 (1999) 259-264
31. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 6 (2000) 1595-1599
32. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 14 (2004) 1730-1737
33. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 8 (2001) 1057-1063
34. Kubota N., Terauchi Y., Yamauchi T., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277 29 (2002) 25863-25866
35. Rothenbacher D., Brenner H., Marz W., and Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 26 16 (2005) 1640-1646
36. Gaudet D., Bouhali T., Couture P., et al. HDL-cholesterol and other covariables associated with CAD-free survival among familial hypercholesterolemic heterozygotes or homozygotes over 70 years of age. Atherosclerosis Suppl 4 2 (2003) 333-334 (Abstract)
37. Isobe T., Saitoh S., Takagi S., et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 153 1 (2005) 91-98
38. Jansen A.C., van Wissen S., Defesche J.C., and Kastelein J.J. Phenotypic variability in familial hypercholesterolaemia: an update. Curr Opin Lipidol 13 2 (2002) 165-171
39. Adamczak M., Rzepka E., Chudek J., and Wiecek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol (Oxford) 62 1 (2005) 114-118
40. CnopF M.H.P., Utzschneider K.M., Carr D.B., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46 4 (2003) 459-469
41. Nishizawa H., Shimomura I., Kishida K., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51 9 (2002) 2734-2741
42. Combs T.P., Berg A.H., Rajala M.W., et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52 2 (2003) 268-276
43. Pajvani U.B., Du X., Combs T.P., et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278 11 (2003) 9073-9085